|
⚲
|
| Keyboard |
| Vida Ventures Management Co LLC
✚
|
|
|---|---|
| CRD # | 315183 |
| SEC # | 802-121751 |
| CIK # | 0001905615, 0001724489 |
| AUM | |
| Employees | |
| Phone | 818-800-5840 |
| Address | 10100 Santa Monica Blvd Los Angeles, CA 90067 |
| Source | [IAPD] [EDGAR] [Website] |
| Total AUM ($) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| VC | Vida Ventures III-A LP | [2021-06-14] | 1.6 M | |
| Offered $750,000,000 · Filed 2021-04-09 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining $750,000,000 · Duration One year or less · Revenue Not Applicable | ||||
| VC | Vida Ventures III LP | [2021-06-14] | 750.0 M | |
| Offered $750,000,000 · Filed 2021-04-09 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining $750,000,000 · Duration One year or less · Revenue Not Applicable | ||||
| AUM Breakdown | Accounts | AUM ($) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 0 | 0.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 0 | 0.0 |
| By Discretionary | ||
| Discretionary | 0 | 0.0 |
| Non-Discretionary | 0 | 0.0 |
| Total | 0 | 0.0 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 0.0 | |
| Total | 0 | 0.0 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Arie Belldegrun | Executive Officer | 50 | 6 | |
| Arjun Goyal | Executive Officer | 15 | 5 | |
| Stefan Vitorovic | Executive Officer | 13 | 4 | |
| Helen Kim | Executive Officer | 21 | 3 | |
| Rajul Jain | Executive Officer | 7 | 2 | |
| Vida Ventures GP III LLC | Executive Officer | 1 | 1 | |
| Jean-Philippe Kouakou-Zebouah | Executive Officer | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 3 | [0001724489] | |
| 4 | [0001724489] | |
| D | [0001724489] | |
| SC 13D | [0001724489] | |
| SC 13G | [0001724489] |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed |
|---|---|---|
| Vida Ventures LLC | Kyverna Therapeutics Inc | [2024-05-03] |
| Vida Ventures LLC | Praxis Precision Medicines Inc | [2021-02-16] |
| Vida Ventures LLC | Kinnate Biopharma Inc | [2021-02-16] |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Vida Ventures III-A LP | |
| Kyverna Therapeutics Inc | |
| Vida Ventures GP III LLC | |
| Vida Ventures III LP | |
| Vida Ventures LLC | |
| Oyster Point Pharma Inc | |
| VV Manager LLC | |
| Q32 Bio Inc |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Kyverna Therapeutics Inc KYTX
Series B Redeemable Convertible Preferred Stock · derivative
|
2024-02-12 | Conversion | 7,356,162 | $0.00 | |
|
Kyverna Therapeutics Inc KYTX
Series A-1 Redeemable Convertible Preferred Stock · derivative
|
2024-02-12 | Conversion | 4,401,771 | $0.00 | |
|
Kyverna Therapeutics Inc KYTX
Series A-2 Redeemable Convertible Preferred Stock · derivative
|
2024-02-12 | Conversion | 8,830,901 | $0.00 | |
|
Kyverna Therapeutics Inc KYTX
Common Stock
|
2024-02-12 | Conversion | 4,523,924 | ||
|
Kyverna Therapeutics Inc KYTX
Common Stock
|
2024-02-12 | Buy | 252,553 | $22.00 | 5,556,166 |
|
Kyverna Therapeutics Inc KYTX
Common Stock
|
2024-02-12 | Buy | 583 | $22.00 | 12,826 |
|
Oyster Point Pharma Inc OYST
Series B Convertible Preferred Stock · derivative
|
2019-11-04 | Conversion | 778,468 | ||
|
Oyster Point Pharma Inc OYST
Common Stock, par value $0.001 per share
|
2019-11-04 | Buy | 185,000 | $16.00 | 2,960,000 |
|
Oyster Point Pharma Inc OYST
Common Stock, par value $0.001 per share
|
2019-11-04 | Conversion | 778,468 | ||
|
Q32 Bio Inc FIXX
Common Stock
|
2018-04-02 | Conversion | 395,845 | $0.00 | |
|
Q32 Bio Inc FIXX
Series B Preferred Stock · derivative
|
2018-04-02 | Conversion | 395,845 | $0.00 | |
|
Q32 Bio Inc FIXX
Common Stock
|
2018-04-02 | Buy | 375,000 | $16.00 | 6,000,000 |